



NEWS RELEASE

Avantor® Closes Previously Announced Divestiture of its Clinical Services Business

2024-10-18

RADNOR, Pa., Oct. 18, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it has closed the divestiture of its clinical services business to Audax Private Equity in a transaction valued at approximately \$650 million. Avantor expects the transaction to result in approximately \$500 million in after-tax cash proceeds and a reduction of approximately \$50 million in capitalized leases. After-tax proceeds will be used to paydown debt.

"This transaction not only strengthens our balance sheet and reduces interest expense, but also enables us to sharpen our focus on strategic growth opportunities in our lab and production businesses," said Michael Stubblefield, President and Chief Executive Officer. "We extend our gratitude to the associates transferring with the business for their invaluable contributions and wish them continued success as they embark on this new chapter under Audax's ownership."

J.P. Morgan Securities LLC served as Avantor's exclusive financial advisor in connection with the transaction and Arnold & Porter LLP served as Avantor's legal advisor. Moelis & Company LLC served as financial advisor to Audax and Ropes & Gray LLP provided legal counsel to Audax.

About Avantor

Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit [avantorsciences.com](https://www.avantorsciences.com) and find us on [LinkedIn](#), [X](#)



(Twitter) and Facebook.

Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, including our cost transformation initiative, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "assumption," "believe," "continue," "estimate," "expect," "forecast," "goal," "guidance," "intend," "likely," "long-term," "near-term," "objective," "opportunity," "outlook," "plan," "potential," "project," "projection," "prospects," "seek," "target," "trend," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.

Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

Global Media Contact

Eric Van Zanten

Head of External Communications

Avantor

610-529-6219

Eric.VanZanten@avantorsciences.com

Investor Relations Contact

Christina Jones

Vice President, Investor Relations

Avantor

805-617-5297

Christina.Jones@avantorsciences.com

View original content:**<https://www.prnewswire.com/news-releases/avantor-closes-previously-announced-divestiture-of-its-clinical-services-business-302279927.html>**

SOURCE Avantor and Financial News